Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization

LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of Parkinson's disease patients. Since a common mutation that replaces Gly(2019) with a serine residue enhances kinase catalytic activity, small-molecule LRRK2 inhibitors might have utility in treating Parkinson...

Descripción completa

Detalles Bibliográficos
Autores principales: Dzamko, Nicolas, Deak, Maria, Hentati, Faycal, Reith, Alastair D., Prescott, Alan R., Alessi, Dario R., Nichols, R. Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631100/
https://www.ncbi.nlm.nih.gov/pubmed/20659021
http://dx.doi.org/10.1042/BJ20100784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631100/
https://www.ncbi.nlm.nih.gov/pubmed/20659021
http://dx.doi.org/10.1042/BJ20100784

Ejemplares similares